The ALLHAT study revisited

do newer data from this trial and others indicate changes in treatment guidelines?

Marvin Moser, Suzanne Oparil, William Cushman, Vasilios Papademetriou

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Following a hypertension symposium in Washington, DC, in November 2006, a panel was convened to discuss new data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and to revisit the significance of this trial in the management of hypertension. Based on these data and information from other trials, the expert panel also addressed the questions, "Is it time for a new Joint National Committee report?" and "Should the 2003 hypertension treatment recommendations be updated or are they still valid?" The panel was moderated by Marvin Moser, MD, Clinical Professor of Medicine, Yale University School of Medicine, New Haven, CT. On the panel were Suzanne Oparil, MD, Professor of Medicine at the University of Alabama in Birmingham, and President of the American Society of Hypertension (ASH); William Cushman, MD, Professor of Preventive Medicine and Medicine at the University of Tennessee in Memphis and attending physician at the Washington, DC, VA Medical Center; and Vasilios Papademetriou, MD, Professor of Medicine at Georgetown University in Washington, DC, and attending physician at the Washington, DC, VA Medical Center. This expert panel discussion was supported by Pfizer Inc and each author received an honorarium from Pfizer Inc for time and effort spent participating in the discussion and reviewing the transcript for important intellectual content prior to publication. The authors maintained full control of the discussion and the resulting content of this article; Pfizer had no input in the choice of topic, speakers, or content.

Original languageEnglish (US)
Pages (from-to)372-380
Number of pages9
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume9
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Antihypertensive Agents
Myocardial Infarction
Medicine
Guidelines
Lipids
Hypertension
Physicians
Preventive Medicine
Clinical Medicine
Therapeutics
Publications

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

The ALLHAT study revisited : do newer data from this trial and others indicate changes in treatment guidelines? / Moser, Marvin; Oparil, Suzanne; Cushman, William; Papademetriou, Vasilios.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 9, No. 5, 01.05.2007, p. 372-380.

Research output: Contribution to journalArticle

@article{e66e0b52254541ff9a7a8765a7c279d7,
title = "The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines?",
abstract = "Following a hypertension symposium in Washington, DC, in November 2006, a panel was convened to discuss new data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and to revisit the significance of this trial in the management of hypertension. Based on these data and information from other trials, the expert panel also addressed the questions, {"}Is it time for a new Joint National Committee report?{"} and {"}Should the 2003 hypertension treatment recommendations be updated or are they still valid?{"} The panel was moderated by Marvin Moser, MD, Clinical Professor of Medicine, Yale University School of Medicine, New Haven, CT. On the panel were Suzanne Oparil, MD, Professor of Medicine at the University of Alabama in Birmingham, and President of the American Society of Hypertension (ASH); William Cushman, MD, Professor of Preventive Medicine and Medicine at the University of Tennessee in Memphis and attending physician at the Washington, DC, VA Medical Center; and Vasilios Papademetriou, MD, Professor of Medicine at Georgetown University in Washington, DC, and attending physician at the Washington, DC, VA Medical Center. This expert panel discussion was supported by Pfizer Inc and each author received an honorarium from Pfizer Inc for time and effort spent participating in the discussion and reviewing the transcript for important intellectual content prior to publication. The authors maintained full control of the discussion and the resulting content of this article; Pfizer had no input in the choice of topic, speakers, or content.",
author = "Marvin Moser and Suzanne Oparil and William Cushman and Vasilios Papademetriou",
year = "2007",
month = "5",
day = "1",
doi = "10.1111/j.1524-6175.2007.06433.x",
language = "English (US)",
volume = "9",
pages = "372--380",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The ALLHAT study revisited

T2 - do newer data from this trial and others indicate changes in treatment guidelines?

AU - Moser, Marvin

AU - Oparil, Suzanne

AU - Cushman, William

AU - Papademetriou, Vasilios

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Following a hypertension symposium in Washington, DC, in November 2006, a panel was convened to discuss new data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and to revisit the significance of this trial in the management of hypertension. Based on these data and information from other trials, the expert panel also addressed the questions, "Is it time for a new Joint National Committee report?" and "Should the 2003 hypertension treatment recommendations be updated or are they still valid?" The panel was moderated by Marvin Moser, MD, Clinical Professor of Medicine, Yale University School of Medicine, New Haven, CT. On the panel were Suzanne Oparil, MD, Professor of Medicine at the University of Alabama in Birmingham, and President of the American Society of Hypertension (ASH); William Cushman, MD, Professor of Preventive Medicine and Medicine at the University of Tennessee in Memphis and attending physician at the Washington, DC, VA Medical Center; and Vasilios Papademetriou, MD, Professor of Medicine at Georgetown University in Washington, DC, and attending physician at the Washington, DC, VA Medical Center. This expert panel discussion was supported by Pfizer Inc and each author received an honorarium from Pfizer Inc for time and effort spent participating in the discussion and reviewing the transcript for important intellectual content prior to publication. The authors maintained full control of the discussion and the resulting content of this article; Pfizer had no input in the choice of topic, speakers, or content.

AB - Following a hypertension symposium in Washington, DC, in November 2006, a panel was convened to discuss new data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and to revisit the significance of this trial in the management of hypertension. Based on these data and information from other trials, the expert panel also addressed the questions, "Is it time for a new Joint National Committee report?" and "Should the 2003 hypertension treatment recommendations be updated or are they still valid?" The panel was moderated by Marvin Moser, MD, Clinical Professor of Medicine, Yale University School of Medicine, New Haven, CT. On the panel were Suzanne Oparil, MD, Professor of Medicine at the University of Alabama in Birmingham, and President of the American Society of Hypertension (ASH); William Cushman, MD, Professor of Preventive Medicine and Medicine at the University of Tennessee in Memphis and attending physician at the Washington, DC, VA Medical Center; and Vasilios Papademetriou, MD, Professor of Medicine at Georgetown University in Washington, DC, and attending physician at the Washington, DC, VA Medical Center. This expert panel discussion was supported by Pfizer Inc and each author received an honorarium from Pfizer Inc for time and effort spent participating in the discussion and reviewing the transcript for important intellectual content prior to publication. The authors maintained full control of the discussion and the resulting content of this article; Pfizer had no input in the choice of topic, speakers, or content.

UR - http://www.scopus.com/inward/record.url?scp=34948910771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948910771&partnerID=8YFLogxK

U2 - 10.1111/j.1524-6175.2007.06433.x

DO - 10.1111/j.1524-6175.2007.06433.x

M3 - Article

VL - 9

SP - 372

EP - 380

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 5

ER -